A series of peptide mimetic substrates of the HIV-1 protease, corresponding substantially to the amino acid sequence of the Tyr-Pro cleavage site contained in the gag polyprotein, in which the tyrosine amino acid of the scissile bond was replaced by?/;" 3-or 4-fluorophenylalanine or 2,2-or 3,3-difluoropA'enylalanine, has been developed. The synthesis of these compounds and the results of inhibition studies are described.
Introduction
The HIV protease is responsible for the processing of the gag and pol gene products. The activity of this enzyme is essential for the assembly and maturation of fully infectious HIV-1 virions (Kohl et al., 1988; Peng et al., 1989) . The inhibition of retroviral proteolytic activity has been reported to occur in the presence of the general aspartyl proteinase inhibitor pepstatin A (Katoh et al., 1987; Giam et al., 1988; Hansen et al., 1988; NUll et al., 1988; Schneider et al., 1988; Seelmeier et et., 1988; Darke et al., 1989; Kraussllch et al., 1989; Richards et et., 1989) . On the basis of its pepstatin inhibition, its primary amino acid sequence and its crystallographic structure (Ratner et et., 1985) , the HIV-1 protease has been classified as an aspartic proteinase (Pearl et al., 1987) . This enzyme was first proposed as a potential target for AIDS therapy by Kramer (Kramer et al., 1986) , who suggested that a frameshift mutation in the proteinase region of the pol gene prevented the processlnq of the gag polyprotein precursor. The HIV protease catalyses hydrolytic cleavage at P1-Pl' (Schechter et al.,1967) peptide bonds such Asn-Phe, Met-Met, Phe-Leu, Phe-Tyr, Leu-Ala, Leu-Phe and particulary Phe-Pro and Tyr-Pro in the Pr 55 gag and Pr 160gag-pol polyproteins present in the immature virion (Table 1 ). The ability of the HIV protease to cleave Phe-Pro and Tyr-Pro sequences is of particular interest in the context of drug development as peptide bonds N-terminal to prolyl residues are normally resistant to cleavage by mammalian endopeptidases. We describe the development of a series of peptide mimetic substrates of the HIV protease. Compounds in which the tyrosine amino acid in the P1 position of the gag polyprotein precursor was replaced by 2-, 3-or 4-fluorophenylalanine or 2,2-or 3,3difluorophenylalanine were evaluated for their potential anti-HIV properties.
Results

Chemistry
From the commercially available L-fluorophenylanines or D,L-difluorophenylalanines, we have prepared a series of small peptides. The 9-f1uorenylmethyloxycarbonyl group (Fmoc) was chosen to protect the amino function of amino acids or peptides (Figs 1-3 ). The hexapeptide 9 (reference compound) was synthesized as follows: the reaction of Fmoc-Phe-OH and H-Pro-OtBu hydrochloride with dicyclohexylcarbodiimide in the presence of t-hydroxybenzotriazole followed by an acidolysis of the obtained Fmoc-Phe-Pro-OtBu 1 by trifluoroacetic acid led to the dipeptide Fmoc-Phe-Pro-OH 2. The tetrapeptide Frnoc-Phe-Pro-Val-Val-OMe 5 was prepared by coupling of the acid dipeptide 2 and the dipeptidic amine H-Val-Val-OMe 4. Compound 4 was synthesized by the coupling of Fmoc-Val-OH and H-Val-OMe hydrochloride with oxalyl chloride in dimethylformamide after removal of the 9-f1uorenylmethyloxycarbonyl group of 3. The pentapeptideFrnoc-Ala-Phe-Pro-Val-Val-OMe 7 was obtained by coupling of Fmoc-Ala-OH with the tetrapeptidic amine 6, which was prepared by removal of the 9-f1uorenylmethyloxycarbonyl group from 5. The hexapeptide Frnoc-Ala-Ala-Phe-Pro-Val-Val-OMe 9 was synthesized by coupling another alanine residue with the pentapeptidic sequence 8 which was prepared by removal of the 9-f1uorenylmethyloxycarbonyl group from 7. These di-, tetra-, penta-and hexapeptides were synthesized to obtain non-fluorinated peptides or reference compounds for the HIV-1 protease or cell assays. The same strategy (Fig. 2) as described above was used for the synthesis of monofluorinated peptides. OMe 21 exhibited the best value, which was nevertheless lower than the pepstatin value. The compounds tested did not exhibit significant inhibitory activities. The very low values obtained did not allow us to perform a study of the influence of the fluorine or of the. length of the peptidic sequence. On the basis of previous studies in the literature, we expected to obtain some better biological activities with longer sequences: penta-or hexapeptides. The in vitro antiviral activities of some compounds were achieved following a colorimetric assay according to Pauwel's method (Pauwels et al., 1988) . None of the compounds tested showed any antiviral activity against HIV in cells assays, and all compounds were toxic to the cells. The least toxic compound was the m-f1uorinated hexapeptide 32 which had an IC 5 0 > 100 J..Lg mr'.
For the difluorinated peptides, we preferred an elongation of the peptidic sequence by successive couplings with amino acids from the N-terminal segment (Fig. 3 ). The difluorinated dipeptides 38 and 39 (Table 2 ) and the tetrapeptides 40 and 41 were obtained in racemic form.
The pentapeptides 44 and 45 were resolved in pure form owing to the separation of the two diastereoisomers A and 8 by column chromatography. The hexapeptides formed (48A, 488, 49A and 498) were optically pure. Some of these compounds have been evaluated for their HIV-1 PR inhibitory effects. 
Biological evaluation
The results of the HIV protease or cell assays are summarized in Tables 2 and 3 . All compounds tested were less active than pepstatin. For assay A, the non-fluorinated pentapeptide 7 and the m-fluorinated pentapeptide 26 exhibited the best values (52 and 41% respectively). For assay S, the best values were obtained for the reference dipeptide 1 (37.5%) and the o-fluorinated pentapeptide 25 (32%). For assay C, the p-f1uorinated tetrapeptide
We chose the sequence Ser-Gln-Asn-Tyr-Pro-Ile-Val, which represents the p17-p24 junction of the HIV-1 gag polyprotein. This heptapeptide was used efficiently as a substrate by the HIV-1 protease . Moreover, a study of the cleavage efficiencies for the various model heptapeptides containing protease cleavage sites of the viral polyprotein gag and pol precursors (SiIlich et al., 1988) showed that the percentage of cleavage of the p17-p24 junction is higher than that of the other sites. It was expected that a length of six (Toth et al., 1990) or seven (Toth et al., 1990; Darke et al., 1988; Moore et al., 1989) amino acid residues would be sufficient to obtain good protease substrates.The hexa-or heptapeptides were of a length to fit into the cleft formed by the HIVt protease. From the natural sequence Gln-Asn-Tyr-Prolie-Val, we carried out some substitutions to obtain the synthetic substrate Ala-Ala-Phs-Pro-Val-Val, which was used by Dreyer . To this substrate, we chose to introduce one or two fluorine atoms on the aromatic ring of the phenylalanine. The aromatic ring could bear a fluorine atom at the ortho, meta or para position to give 2-, 3-or 4-fluorophenylalanine, respectively, but could also carry two fluorine atoms at the ortho-ortho or meta-meta position to give 2,2-or 3,3-difluorophenylalanine, respectively. Fmoc Fmoc
Fmoc CDaOD as the internal standard. The notation and symbols used for the characterization of the hydrogens of the phenyl and 9-fluorenylmethyloxycarbonyl groups are presented in Fig. 4 . MS spectra (FAB analysis) were obtained on a JEOL JMS DX 300 mass spectrometer (matrix: glycerol), and were recorded on a Nermag R 10-1OCquadripolar instrument by electronic impact or chemical ionization (vector gas: isobutane). The purity was estimated by HPLC on a Merk L-6200 apparatus with a UV L-4000 detector and a C18 Merck Interchrom column (<I> : 3·9 mm and I : 250 mm) or was obtained using a Waters apparatus with a UV 440 detector (254 nm) and an r-421 differential refractometer. All chromatographic purifications were carried out on Merck silica gel 60H. Thin layer chromatography (TLC) was performed on Merk silica gel 60F plates. The compounds were visualized directly under UV light (254 nm) and/or by spray basic solution of 5% ninhydrin in ethanol or by spray acidic solution (a mixture of acetic and sulfuric acid).
All hexapeptides were synthesized following standard procedures described in the literature. All amino acids were purchased from either Novabiochem or Yarsley and all reagents from Aldrich or Fluka. The 9-f1uorenylmethyloxycarbonyl group (Fmoc) was used as the protecting agent of amino functions (procedure i), and dicyclohexylcarbodiimide (DCC) in the presence of 1-hydroxybenzotriazole (H08t) (procedure ii) or oxalyl chloride was used as the coupling reagent. The removal of the 9-fluorenylmethyloxycarbonyl group was achieved using diethylamine (DEA) (procedure iii) and the acidolysis of the telt-butyl ester of proline was carried out with trifluoroacetic acid (TFA) (procedure iv). All procedures are given below.
Typical N-9-fluorenylmethyloxycarbonyl group protection of amino function (procedure i) An amino acid (1 mmol) was dissolved in a 10% solution of sodlum carbonate in water (7 ml) and in dioxane (4 ml). 9-Fluorenylmethyl chlorocarbonate (Frnoc-Cl) (1 mmol) was added in small portions at 0°C to a solution of amino acid (1 mmol). The reaction mixture was stirred for 20 h at room temperature. After acidification with HCI 12 N at O°C with vigorous stirring, the mixture was extracted with ethyl acetate. The organic phases were collected, dried over anhydrous sodium sulfate and evaporated to dryness in vacuo. The Fmoc-protected amino acid was triturated with ether and hexane to precipitate the amino acid.
Typical coupling reactions with dicyclohexylcarbodiimide and 1-hydroxybenzotriazole (procedure ii)
An amino acid or peptide (1 mmol) was dissolved in dimethylformam ide (5 ml). The hydrochloride form of the amino acid or peptide (1 mmol), N-methylmorpholine (1 mmol) and 1-hydroxybenzotriazole (1 mmol) were added. The solution was stirred and cooled in an ice-water bath while dicyclohexylcarbodiimide (1.1 mmol) was added. The reaction mixture was stirred for 20 h at room temperature. Ethyl acetate was added to the reaction mixture to give precipitation of N,N'-dicyclohexylurea, which was removed by filtration. The mixture was concentrated under vacuum to 10 ml, diluted with ethyl acetate (10 ml) and washed with citric acid (10%), with sodium hydrogen carbonate (10%) and with brine solution. The organic layer was dried over anhydrous sodium sulfalte, filtered and evaporated to dryness in vacuo.
Removal of the 9-fluorenylmethyloxycarbonyl group (procedure iii)
Diethylamine (2 ml) was added to a solution of the protected peptide (1 mmol) dissolved in dichloromethane (2 ml). The mixture was stirred at room temperature for 2 h, and was then evaporated to dryness in vacuo. The residue was dissolved in ethyl acetate and acidified under vigorous stirring with 1N hydrochloric acid to Red Congo. The aqueous phase was cooled in an ice-water bath and the pH was then adjusted to 10 by the addition of concentrated liquid ammonia. The aqueous phase was extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous sodium sulfate, filtered and evaporated to dryness in vacuo. The free amino peptide ester was used without further purification. The peptide hydrochloride was prepared by adding hydrochloric acid saturated ether to the free amino peptide, and then evaporating to dryness in vacuo.
Acidolysis of the tert-butyl ester of proline (procedure iv)
A dipeptide (1 mmol) in dichloromethane (2 ml), acidified at 0 bC with trifluoroacetic acid (2 ml), was stirred for 1.5 h at room temperature to obtain the complete disappearance of the ester (followed by TLC). The reaction mixture was concentrated in vacuo to 2 ml, diluted with ethyl acetate, washed with water, dried over anhydrous sodium sulfate and evaporated to dryness in vacuo. The Fmoc-protected dipeptide was used without further purification. (Phe(F)p2CH o, d, 3J C _ F= 8 Hz); 127.8 (Fmoc 2CH(2»; 127.1 (Fmoc 2CH(3»; 125.2 (Fmoc 2CH(1»; 120.1 (Fmoc 2CH(4»; 115.2 (Phe(F) p 2CH m, d, 2Je-F = 21 Hz); 67.2 (Fmoc CH 2); 59.8 and 59.1 (2Val u-CH); 57.1 (Pro u-CH); 52.2 (CH 30); 51.8 (Phe(F)p u-CH); 50.6 and 48.6 (2Ala u-CH); 47.7 (Pro o,o'-CH 2); 47.2 (Fmoc CH); 37.9 (Phe(F)p~,W-CH2); 31.2 and 30.9 (2Val [3-CH); 29.2 (Pro J3,J3'-CH 2 ) ; 24.9 (Pro y;y'-CH 2); 19. . Fmoc-Ala-Phe(F,F)o,o-Pro-Val-Val-OMe (44) was obtained by coupling Fmoc-Ala-Ol-i with fragment 42 (procedure ii). This fragment was prepared by removal of the 9-f1uorenylmethyloxycarbonyl group from 40 (procedure iii). Using column chromatography the two diastereoisomers (L,L,L,L,L and L,O,L,L,L) were separated and the pure pentapeptides (CH 2CI 2/AcOEt, 3:7, v/v) obtained. The first pentapeptide eluted was the diastereoisomer 44A, followed by the diastereoisomer 448. (N-9-Fluorenylmethyloxycarbonyl) alaninyl-3,3-difluorophenylalaninylprolylvalinylvaline methyl ester (diastereoisomer A) (45). Fmoc-Ala-Phe(F,F)m,m-Pro-Val-Val-OMe (45) was obtained by coupling Fmoc-Ala-OH with fragment 43 (procedure ii). This fragment was prepared by removal of the 9-fluorenylmethyloxycarbonyl group from 41 (procedure iii). A column chromatography was used to separate the two diastereoisomers (L,L,L,L,L and L,O,L,L,L) and to obtain the pure pentapeptides (CH 2CI2/AcOEt, 3:7, v/v) . The first pentapeptide eluted was the diastereoisomer 45A, followed by the diastereoisomer 458. alaninylalaninyl-3,3-difluorophenylalaninylprolylvalinylvaline methyl ester (diastereoisomer A) (49A). Fmoc-Ala-Ala-Phe(F,F)m,m-Pro-Val-Val-OMe (49A) was obtained by coupling Fmoc-Ala-OH with fragment 47A (procedure ii). This fragment was prepared by removal of the 9fh,JOrenylmethyloxycarbonyl group from 45A (procedure iii).
Preparation of monofluorinated peptides
Preparation of difluorinated peptides
The residue was chromatographed (CH 2CI2/AcOEt, 1:9, v/v) to yield 49A (76%). R, = 0.68 (MeOH/AcOEt, 0.5:19.5, vlv); lH NMR (CDCI 3) 8 (ppm) 7.96 (1H; d; 3J=9.1 Hz; Ala NH); 7. 76 (2H; d; 3J=6.9 Hz; Fmoc H(4»; 7.66 (2H; d; 3J=6.9 Hz; Fmoc H(l»; 7.35 (4H; m; Fmoc H(3) Ala a-CH); 4.65 (1H; m; Pro a-CH); 4.55 (1H; dd; 3J=8.7 Hz; 3J =4.9 Hz; Val a-CH); 4.36 (1H; m; Ala a-CH); 4.36 (2H; m; Fmoc CH 2); 4.26 (1H; m; Val a-CH); 4.20 (1H; m; Fmoc CH); 3.72 (3H; s; OMe); 3.72 (1H; m; Pro 8'-CH); 3.40 (1H; m; Pro 8-CH); 3.03 (1H; dd; 2J=13.5 Hz; 3J=5.8 Hz; Phe(F,F)m,m W-CH); 2.91 (1H; dd; 2J = 13.5 Hz; 3J = 5.8 Hz; Phe(F,F)m,m 13-CH); 2.15 (2H; m; Vall3-CH); 2.00 (4H; m; Pro I3,W and y;y'-CH); 1.36 (3H; d; 3J = 6.8 Hz; Ala I3-CH 3 ) ; 1.20 (3H; d; 3J = 6.3 Hz; Ala I3-CH 3); 0.90 (12H; m; Val 
Materials and Experimental procedures: virology
HIV Protease assays
The fluorinated compounds were evaluated as HIV protease inhibitors by Rhone Poulenc-Rorer using three different HIV-1 enzyme substrate cleavage assays. The first assay (A), in which succinyl-Thr-Leu-Asn-Phe-Pro-lie-Ser-MCA was used as substrate, gave the percentage inhibition after 1 h of incubation at 37 DC, without taking the initial rate into account. Assay (B) was carried out with Val-Ser-Gln-Asn-Phe(N0 2)-Pro-lie-Val as f1uorogenic substrate in 1M NaCI solution at 37 DC, taking the initial rate into account and measuring the increase of the optical density at 307 nm. In assay C the BACHEM HIV-substrate III, His-Lys-Ala-Arg-Val-Leu-Phe(N0 2)-Glu-Ala-Nle-Ser-NH2 was used, the conditions being the same as those in assay B, taking the initial rate into account and measuring the decrease in the optical density at 300 nm. The compounds were tested at a concentration of 10-5 M using the pepstatin inhibition as reference. All inhibition percentages are listed in Tables 2 and 3 .
Antiviral assays
The in vitro antiviral activities of the fluorinated compounds were determined by the inhibition of the cytopathic effect (CPE) of HIV-1 (strain LAI) in CEM-4 cells. The relative numbers of viable cells were determined by the MTI [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] reduction procedure to formazan.
